120,000 Shares in Urogen Pharma $URGN Acquired by Elmind Capital LP

Elmind Capital LP acquired a new stake in shares of Urogen Pharma (NASDAQ:URGN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 120,000 shares of the company’s stock, valued at approximately $4,416,000,000. Urogen Pharma accounts for about 1.1% of Elmind Capital LP’s investment portfolio, making the stock its 22nd biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC acquired a new position in shares of Urogen Pharma during the second quarter valued at $11,064,000. Partners Capital Investment Group LLP acquired a new stake in shares of Urogen Pharma in the 2nd quarter worth about $566,000. California State Teachers Retirement System increased its holdings in shares of Urogen Pharma by 1,605.5% in the 1st quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock worth $697,000 after acquiring an additional 36,478 shares during the period. Swiss National Bank bought a new stake in Urogen Pharma in the 1st quarter valued at about $1,399,000. Finally, SG Americas Securities LLC lifted its position in Urogen Pharma by 20.3% in the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after purchasing an additional 280,199 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Stock Up 0.4%

Shares of URGN opened at $46.36 on Wednesday. The firm has a market capitalization of $2.27 billion, a PE ratio of -23.41 and a beta of 1.57. The firm has a 50-day moving average price of $41.11 and a 200 day moving average price of $29.51. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. On average, equities analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on URGN shares. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Oppenheimer boosted their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Guggenheim increased their price objective on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.38.

Insider Activity

In related news, insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider owned 59,086 shares in the company, valued at $2,779,996.30. This trade represents a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 85,899 shares of company stock valued at $3,747,513 in the last ninety days. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.